Applications of 3-[(3-Cholamidopropyl)Dimethylammonio]-2-Hydroxy-1-Propanesulfonate in Industrial Manufacturing

As a direct manufacturer, we supply 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate to industrial clients who operate advanced bioprocessing, diagnostics, and specialty ingredient platforms. Our commitment to application-driven quality and transparency ensures that our clients receive material formulated for demanding downstream use. Below, we detail major adoption segments with exacting technical requirements, process integration points, and compliance factors as verified by ongoing feedback from large-scale producers.

1. Membrane Protein Solubilization for Biopharmaceutical Production

Biopharmaceutical manufacturers rely on this zwitterionic detergent as a critical reagent for extracting, purifying, and stabilizing membrane-bound proteins such as GPCRs and ion channels. Its unique charge and hydrophilic properties minimize protein denaturation and preserve biological activity throughout the purification workflow, including chromatography and crystallography stages. Global innovator drug pipelines and contract manufacturers require tight control of detergent parameters to support GLP and GMP compliant production.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• FDA 21 CFR part 210/211 (as adjunct to API/DS manufacturing)
• USP <1059> Excipient Functionality
• European Pharmacopoeia (EP) general chapter for Biotechnological Products

Typical usage ratio

• 0.5–2.0% w/v, adjusted per protein class and process stage; concentration set via pre-formulation studies and validated in scale-up runs

Downstream process integration

• Added during cell lysis and solubilization step for membrane extraction
• Present in buffer systems for affinity and ion exchange chromatography
• Carried through in buffer exchanges prior to concentration and polishing
• Optional inclusion in formulation buffers for storage stability

Final product types

• Monoclonal antibodies (mAbs)
• Therapeutic recombinant membrane proteins
• Biologic drug substance intermediates
• Protein structure cocrystal screening samples

2. Lysis Buffer Component for DNA/RNA Extraction Kits

Molecular diagnostics and biotechnology kit manufacturers select this material as a defined detergent for lysing cultured or clinical cells prior to DNA and RNA purification. Its compatibility with downstream nucleic acid amplification and detection enables high-yield workflows with minimal interference, supporting regulated production and global logistics for OEMs and branded suppliers of diagnostic consumables.

Industry compliance standards

• ISO 13485 Quality Management for Medical Devices and IVD
• FDA 21 CFR part 820 (Quality System Regulation for medical devices)
• Chinese GB/T 16886.1 Biological Evaluation of Medical Devices
• REACH Annex XVII for chemical safety

Typical usage ratio

• 0.1–1.0% w/v in premixed lysis buffer, titrated according to sample type and downstream nucleic acid platform compatibility

Downstream process integration

• Direct addition to proprietary lysis buffer formulations
• Combined with protease inhibitors and chelators to ensure intact nucleic acids
• Buffer transfer into automated extraction platforms or spin-column/pipette device formats

Final product types

• Automated DNA/RNA extraction kits
• Manual spin-column nucleic acid purification kits
• Sample preparation reagents for clinical diagnostics
• Lysis buffers for research and reference laboratory use

3. Sample Preparation Reagent for Proteomics & Mass Spectrometry

Specialty analytical laboratories and proteomics service providers use this compound for solubilizing cell and tissue proteins in highly controlled pre-analytical workflows supporting LC-MS/MS and 2D electrophoresis. It offers reliable protein extraction efficiency with low MS background and minimal interference in peptide mass fingerprinting, meeting QC parameters for regulatory submissions and high-throughput clinical proteomics pipelines.

Industry compliance standards

• CLSI C54-A Proteomics Applications Standards
• ISO/IEC 17025 Accredited Testing Laboratories
• CAP Laboratory Accreditation Program for Clinical Proteomics
• FDA CFR Title 21 (if results used for regulated studies)

Typical usage ratio

• 1.0–2.5% w/v in solubilization buffer; concentration set based on starting matrix and target proteins, with QC testing for MS compatibility

Downstream process integration

• Prep buffer for cell or tissue lysate generation
• Protein solubilization prior to reduction, alkylation, and digestion steps
• Optional wash steps to reduce residual background contaminants

Final product types

• Quantitative proteomics kits
• Sample preparation modules for LC-MS/MS
• Clinical proteomics research consumables
• Protein extraction reagents for academic and CRO labs

4. Zwitterionic Surfactant in Membrane Protein Crystallization

Structural biology labs and crystallography reagent suppliers formulate this detergent into screening kits for the growth of high-quality membrane protein crystals. Its chemical structure allows efficient modulation of protein-lipid-detergent microenvironments within vapor diffusion and microbatch crystallization formats, which is critical for reproducible crystal formation needed in structural determination.

Industry compliance standards

• ISO 9001:2015 for research chemical manufacturing
• OECD GLP for structure-activity and structure-function studies
• Analytical and Research-Grade Evaluation Standards (as required by academic or pharma partners)

Typical usage ratio

• 0.01–1.0% w/v, optimized per protein, combined empirically with lipid mixtures and precipitating agents for each crystallization screen

Downstream process integration

• Prepared as part of defined crystallization reagent sets for robotic or manual setup
• Mixed with purified protein pre-screening and during vapor diffusion or microbatch setup
• Washed out post-crystal formation before X-ray diffraction or EM analysis

Final product types

• Protein crystallization screening kits
• Custom buffer sets for crystallographers
• Research-use-only crystallization reagent packs
• Membrane protein structural determination consumables

5. Detergent for Virus Inactivation in Biologic Processing

Suppliers of plasma-derived medicines and cell-based bioproducts include this compound in validated virus inactivation stages to disrupt lipid envelopes of potential contaminants without compromising protein structure or activity. Strict process validation protocols require quantitative removal post-inactivation, as well as documentation of detergent performance and full traceability under cGMP conditions.

Industry compliance standards

• ICH Q5A (R2) Viral Safety Evaluation of Biotechnology Products
• EU GMP Volume 4, Annex 2 (Manufacture of Biological Active Substances)
• FDA Guidance for Industry: Virus Filtration/Removal

Typical usage ratio

• 0.3–1.0% w/v, determined based on viral load, processing time, and target protein stability; validated by virus spiking studies and recovery assays

Downstream process integration

• Added to bulk intermediate protein solutions after primary purification
• Followed by detergent removal steps such as ultrafiltration, chromatography, or diafiltration
• In-process QC to verify detergent clearance and functional protein integrity

Final product types

• Plasma-derived therapeutics (IVIG, albumin, clotting factors)
• Recombinant therapeutic proteins requiring viral clearance
• Bulk biologic drug substances prior to fill and finish